Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations.
D000477:Alkylating Agents / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000378:metabolism / Q000494:pharmacology; D000963:Antimetabolites / Q000378:metabolism / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000378:metabolism*; D001215:Asparaginase / Q000378:metabolism / Q000494:pharmacology; D001665:Binding Sites; D004254:DNA Nucleotidyltransferases / Q000378:metabolism; D004273:DNA, Neoplasm / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D005938:Glucocorticoids / Q000378:metabolism / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism*; D007700:Kinetics; D051379:Mice; D011485:Protein Binding / Q000187:drug effects; D012313:RNA / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D012316:RNA Nucleotidyltransferases / Q000378:metabolism; D051381:Rats
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D012313:RNA; D004254:DNA Nucleotidyltransferases; D012316:RNA Nucleotidyltransferases; D001215:Asparaginase